[CAS NO. 432529-82-3] BCI-121
PRODUCTS SPECIFICATIONS [432529-82-3]
DESCRIPTION [432529-82-3]
Overview
| MDL | MFCD02149239 |
|---|---|
| Molecular Weight | 340.22 |
| Molecular Formula | C14H18BrN3O2 |
| SMILES | NC(C1CCN(CC(NC2=CC=C(Br)C=C2)=O)CC1)=O |
2 Publications Citing Use of MCE
In Vitro
BCI-121 significantly inhibits SMYD3-substrate interaction and chromatin recruitment and is effective in reducing proliferation in various cancer cells types. BCI-121 significantly reduces proliferation of HT29 (by 46%) and HCT116 (by 54%) cells at 72 h and decreases the expression levels of SMYD3 target genes. SMYD3 preferentially methylates histone H4, and the presence of BCI-121 impairs SMYD3-mediated H4 in vitro methylation. Cancer cells treated with BCI-121 show a significant reduction in their growth ability and accumulated in the S phase of the cell cycle. Cells treated with BCI-121 shows a dose-dependent relationship between SMYD3 impairment and both inhibition of proliferation and reduction of targeted methyl marks (H4K5me and H3K4me2). BCI-121 shows antiproliferative properties in cancer cell lines overexpressing SMYD3 and, in general, replicated the effects of SMYD3-targeted RNAi. Experiments performed in cancer cells show that BCI-121 prevents SMYD3 recruitment on the promoters of its target genes and this event is correlated with reduced gene expression [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 293.93 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.9393 mL | 14.6964 mL | 29.3927 mL |
| 5 mM | 0.5879 mL | 2.9393 mL | 5.8785 mL |
| 10 mM | 0.2939 mL | 1.4696 mL | 2.9393 mL |